



Myomo Welcomes 13 New Center of Excellence Locations

Expands Availability of MyoPro® Powered Arm Brace to 46 Locations Nationwide

March 12, 2018 08:00 AM Eastern Daylight Time

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a commercial stage medical robotics company, today announced the addition of three new orthotics and prosthetics (O&P) practices and 13 new locations to its MyoPro Center of Excellence (CoE) program, which recognizes top O&P practices that support the MyoPro line of powered orthoses. The addition of the practices brings the total number of CoE locations across the United States to 46.

MyoPro Centers of Excellence have met Myomo's exacting standards for providing quality patient care and have proven their expertise in evaluating candidates and fitting them with the MyoPro powered upper limb orthotic. MyoPro is currently the only lightweight wearable device that can help restore function in the paralyzed or weakened arms and hands of individuals who have suffered a stroke, brachial plexus injury (BPI) or other neuromuscular disability.

The new CoE practices and locations announced today include:

- Wright & Filippis, Michigan's largest O&P practice; locations supporting MyoPro in Kalamazoo, Battle Creek, Flint, Lansing, Livonia, Ann Arbor, Madison Heights, Detroit, Saginaw and Clinton Township
- East Coast Orthotic & Prosthetic (ECOP); locations in Deer Park, New York and Buffalo, New York
- Bionics Orthotics & Prosthetics; location in San Diego, California

Myomo CoEs participate in joint marketing efforts and receive training and patient support from Myomo. They also partner with physicians and therapists at leading U.S. rehabilitation hospitals, who recommend and prescribe MyoPro as well as train new MyoPro users.

"The expanding MyoPro Center of Excellence program affords patients the opportunity to receive quality care closer to their homes," said Paul R. Gudonis, Chairman and CEO of Myomo. "Our goal is to make MyoPro readily accessible to as much of the U.S. population as possible within this year."

About Myomo

Myomo, Inc. is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are



able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.

Forward Looking Statements

This press release contains forward-looking statements regarding the Company's future business expectations, the addition of the new CoE locations and the commercialization of our MyoPro product, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Our actual results could differ materially from those anticipated in these forward looking statements for many reasons, including, without limitation, risks related to regulatory approval and market acceptance of our products, and the other risk factors contained in our filings made with the Securities and Exchange Commission. More information about factors that potentially could affect Myomo's financial results is included in Myomo's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contacts

For Myomo:

ir@myomo.com

or

Investor Relations:

PCG Advisory

Vivian Cervantes, 646-863-6274

vivian@pcgadvisory.com

or

Public Relations:

Greenough

Rachel Robbins, 617-275-6521

rrobbins@greenough.biz